CorMedix DefenCath Evaluated to Prevent Catheter-Related Bloodstream Infections in Hemodialysis

December 29, 2025—CorMedix Therapeutics announced interim results for the company’s ongoing real-world study of its DefenCath (taurolidine and heparin) to prevent catheter-related bloodstream infections (CRBSI) in adult patients receiving hemodialysis with central venous catheters.

According to the company, the study is designed to demonstrate the impact of the broad use of DefenCath in a real-world setting and prospectively assess rates of CRBSI for 2 years as well as hospitalizations secondary to these infections. Secondary data points include missed treatment sessions, antibiotic utilization, and utilization of tissue plasminogen activator.

The study is being conducted in conjunction with U.S. Renal Care’s (USRC) use of DefenCath. Currently, more than 3,000 patients per month are receiving DefenCath on a routine basis at USRC facilities. CorMedix conducted a preliminary analysis of interim data for approximately 7,000 patients who received at least one dose of DefenCath in Year 1.

CorMedix advised that the company’s analysis of the data available through September 30, 2025, demonstrated that use of DefenCath resulted in an overall 72% reduction in CRBSI and a 70% reduction in hospitalizations secondary to CRBSI compared to historical controls.

The press release noted CorMedix and USRC commenced the study upon outpatient commercial launch of DefenCath in July 2024. This large, prospective, ongoing real-world study seeks to underscore the findings from the LOCK-IT 100 clinical study that were the basis for FDA approval of DefenCath for hemodialysis in end-stage renal disease patients.